F041 Novel Insights in Rare Diseases (NIRDs)
DESCRIPTION
Rare diseases need our attention! Both on the diagnosis and therapeutic fronts, there is a great deal to learn about rare diseases. Several have new therapies have emerged and continue to be approved every few weeks. The pedagogical approach to managing patients with a new constellation of manifestations and using novel biologics or drugs can be challenging for the busy clinician. How should we develop a strategy to be learning constantly about rare diseases? How can we keep up with all the advances around us? How can we adopt novel treatment options into our comfort zone and therapeutic options for our patients? This session will go beyond simple tactics to going further and developing an index of suspicion for diagnosing rare skin diseases with systemic manifestations, and treating specific groups of rare diseases – we will channel our learning to learn how to keep up and keep growing our repertoire on a continuing basis. The patients we serve expect cutting edge thinking and management – as dermatologists we are up to the task!
LEARNING OBJECTIVES
Diagnose rare diseases in pediatric and adult patients, with new index of suspicion training
Identify novel mechanism-of-action medications and biologics matched to rare diseases
Utilize a wide array of strategies to manage patients with rare diseases
SCHEDULE
3:30 PM
Pediatric rare diseases I do not want to miss
Sadaf Hussain, MD, FAAD
3:55 PM
A new tack on rare mast cells disorders and new treatments
Adel S. Haque, MD, FAAD
4:20 PM
Blistering pace of emerging B cell therapies for rare diseases
Abrar A. Qureshi, MD, MPH, FAAD
4:45 PM
Index of suspicion in rare collagen vascular diseases and novel therapies
Nadine Kaskas, MD, FAAD
5:10 PM
Targeted therapies in neutrophilic dermatoses (pustular psoriasis, hidradenitis suppurativa, pyoderma gangrenosum)
Shadi Khalil, MD, PhD, FAAD
DIRECTOR
Abrar A. Qureshi, MD, MPH, FAAD
SPEAKERS
Adel S. Haque, MD, FAAD
Sadaf Hussain, MD, FAAD
Nadine Kaskas, MD, FAAD
Shadi Khalil, MD, PhD, FAAD
DISCLOSURES
Adel S. Haque, MD, FAAD
No financial relationships exist with ineligible companies.
Sadaf Hussain, MD, FAAD
No financial relationships exist with ineligible companies.
Nadine Kaskas, MD, FAAD
No financial relationships exist with ineligible companies.
Shadi Khalil, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Abrar A. Qureshi, MD, MPH, FAAD
Galderma – Consultant (1099 relationship)(Honoraria); Incyte Corporation – Consultant (1099 relationship)(Honoraria); OM1, Inc – Consultant (1099 relationship)(Honoraria); UCB – Consultant (1099 relationship)(Honoraria);